Adenosine A
11C-preladenant PET
Parkinson's disease
adenosine A2A receptor
caffeine
coffee
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
07
12
2021
received:
31
08
2021
accepted:
09
12
2021
pubmed:
11
1
2022
medline:
20
4
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Coffee intake can decrease the risk for Parkinson's disease (PD). Its beneficial effects are allegedly mediated by caffeine through adenosine A We aimed to calculate occupancy rates of striatal A Five patients with PD underwent The mean serum caffeine level (μg/mL) was 0.374 at baseline and increased to 4.48 and 8.92 by 129.5 and 259 mg of caffeine, respectively. The mean occupancy rates of striatal A A sufficient A
Sections du résumé
BACKGROUND
Coffee intake can decrease the risk for Parkinson's disease (PD). Its beneficial effects are allegedly mediated by caffeine through adenosine A
OBJECTIVE
We aimed to calculate occupancy rates of striatal A
METHODS
Five patients with PD underwent
RESULTS
The mean serum caffeine level (μg/mL) was 0.374 at baseline and increased to 4.48 and 8.92 by 129.5 and 259 mg of caffeine, respectively. The mean occupancy rates of striatal A
CONCLUSIONS
A sufficient A
Identifiants
pubmed: 35001424
doi: 10.1002/mds.28897
pmc: PMC9306703
doi:
Substances chimiques
Coffee
0
Receptor, Adenosine A2A
0
Caffeine
3G6A5W338E
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
853-857Informations de copyright
© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Neurology. 2017 Oct 24;89(17):1795-1803
pubmed: 28954882
Synapse. 1997 Dec;27(4):322-35
pubmed: 9372555
J Nucl Med. 2017 May;58(5):762-767
pubmed: 28062599
Int Rev Neurobiol. 2014;119:xv-xvi
pubmed: 25175975
Biol Psychiatry. 2007 Oct 15;62(8):878-83
pubmed: 17662961
Purinergic Signal. 2020 Jun;16(2):167-174
pubmed: 32236790
Am J Psychiatry. 2006 Mar;163(3):396-401
pubmed: 16513859
Neuropharmacology. 2018 Dec;143:106-112
pubmed: 30253174
Life Sci. 2014 Apr 17;101(1-2):1-9
pubmed: 24530739
Pharmacol Rev. 2018 Apr;70(2):384-411
pubmed: 29514871
Neurology. 2003 Dec 9;61(11 Suppl 6):S97-100
pubmed: 14663020
Neuroimage. 1996 Dec;4(3 Pt 1):153-8
pubmed: 9345505
J Cereb Blood Flow Metab. 2002 Dec;22(12):1440-52
pubmed: 12468889
Mov Disord. 2012 Sep 1;27(10):1276-82
pubmed: 22927157
J Alzheimers Dis. 2014;41(4):961-1019
pubmed: 24898652
Mov Disord. 2013 Jul;28(8):1138-41
pubmed: 23483627
Neuropsychopharmacology. 1996 Dec;15(6):562-6
pubmed: 8946430
J Neural Transm (Vienna). 2018 Aug;125(8):1273-1286
pubmed: 29396609
Ann Neurol. 2002 Sep;52(3):276-84
pubmed: 12205639
Planta Med. 2017 Nov;83(16):1256-1263
pubmed: 28675917
Mov Disord. 2021 Jan;36(1):268-269
pubmed: 33200448